Conclusions and final thoughts
Michael O’Neill and Michael Hopkins
We set out to explain in plain language key factors to consider when launching and guiding a company through the early stages of therapeutic development in the biotech industry. Along the way through the broad range of topics covered, we have tried to give a realistic overview of the challenges and risks involved.
The difficulties in transforming basic science into promising drugs are almost reminiscent of the alchemy of old, trying to find the secret of turning base metal into gold. Successful drugs have been likened to Taleb’s Black Swans – so extremely rare that sightings are entirely unpredictable (Munos, 2009). For most, the best chance of finding a promising ...